Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Table 3 Distribution of metastases at baseline and most recent follow-up

Location of metastases	# of patients (%)^a at baseline	# of patients (%)^a at most recent follow-up
Lung	9 (56.3)	10 (62.5)
Liver	9 (56.3)	9 (56.3)
Lymph nodes	2 (12.5)	5 (31.3)
Subcutaneous	4 (25.0)	4 (25.0)
Other soft tissue	5 (31.3)	6 (37.5)
Total # of patients with metastases	16 (100.0)	16 (100.0)

^aPercentages based on 16 patients found to have metastases. Eleven patients (68.8 %) had bone metastases, which were not evaluable by volumetric segmentation. Values were obtained by retrospective analysis; thus two patients with unnoticeable metastatic disease at baseline are included

ISSN: 1471-2407